Core Insights - Regeneron Pharmaceuticals is set to present new clinical data for EYLEA HD at the Angiogenesis annual meeting on February 7, 2026, highlighting its efficacy and safety in treating serious retinal diseases [1][2] Group 1: EYLEA HD Overview - EYLEA HD (aflibercept) Injection 8 mg has been approved by the FDA for treating macular edema following retinal vein occlusion (RVO), providing the first every-two-month treatment option for patients who previously required monthly treatments [2][10] - The Phase 3 QUASAR trial demonstrated that EYLEA HD met its primary endpoint at 36 weeks, with final long-term results to be presented at the upcoming meeting [2][3] - EYLEA HD aims to offer comparable efficacy and safety to the original EYLEA but with fewer injections, thus improving patient convenience [7][8] Group 2: Clinical Trials and Data - The Phase 3b ELARA trial will present full primary data for EYLEA HD dosed every 4 weeks in patients with wet age-related macular degeneration (wAMD) or diabetic macular edema (DME) [3] - Data from the ELARA trial supports the approval of EYLEA HD as a monthly treatment option for patients who require more frequent dosing, showing that patients switching from other anti-VEGF agents generally improved their vision [2][3] Group 3: Safety and Adverse Reactions - Common adverse reactions (≥3%) reported in patients treated with EYLEA HD include cataract, conjunctival hemorrhage, and increased intraocular pressure [4][10] - The safety profile of EYLEA HD is consistent with that of EYLEA, with potential side effects including eye pain, retinal hemorrhage, and blurred vision [4][12] Group 4: Upcoming Presentations - Regeneron will present various studies at the Angiogenesis meeting, including the correlation of foveal invasion with visual function and the safety and efficacy of aflibercept 8 mg in patients with nAMD or DME [5]

Regeneron Corporate Presentation J A N U A R Y 2 0 2 6 2 Integrating Genetics, Proteomics, and Big Data World's largest DNA and proteomics-linked healthcare database, enabling advanced drug discovery, development, and healthcare analytics This non-promotional presentation contains investigational data as well as forward-looking statements; actual results may vary materially. Note regarding forward-looking statements and non-GAAP financial measures This presentation includes forward-looking statements that i ...